(Q38088261)

28 August 2017

title

Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections (English)

1 reference

28 August 2017

0 references

3

Po-Ren Hsueh

1 reference

28 August 2017

Yen-Hsu Chen

1

1 reference

28 August 2017

Wen-Chien Ko

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 April 2013

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

587-596

1 reference

Antimicrobials in urogenital infections

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Changing bacteriology of abdominal and surgical sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Editorial commentary: extended-spectrum β-lactamase-producing escherichia coli in the united states: time to rethink empirical treatment for suspected E. coli infections?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Consensus statement on the role of fluoroquinolones in the management of urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Pseudomonas aeruginosa: all roads lead to resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Effectiveness and safety of colistin: prospective comparative cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Urinary catheter-associated infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Surveillance on secular trends of incidence and mortality for device-associated infection in the intensive care unit setting at a tertiary medical center in Taiwan, 2000-2008: a retrospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Vancomycin-resistant enterococcal urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Surveillance of catheter-associated urinary tract infection in 4 intensive care units at Alexandria university hospitals in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

The rise of the Enterococcus: beyond vancomycin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Treatment of resistant enterococcal urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Management of multidrug-resistant enterococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

New drugs for Gram-positive uropathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Tigecycline pharmacokinetic/pharmacodynamic update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Emergence of tigecycline-resistant Klebsiella pneumoniae after tigecycline therapy for complicated urinary tract infection caused by carbapenem-resistant Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Excess deaths associated with tigecycline after approval based on noninferiority trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Resistance profiles of urinary tract infections in general practice--an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Nitrofurantoin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Successful treatment of vancomycin-resistant Enterococcus faecium pyelonephritis with daptomycin during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Determination of linezolid in human serum and urine by high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Rapid control of an outbreak of vancomycin-resistant enterococci in a French university hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Effect of linezolid on the occurrence of vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Impact of a region wide antimicrobial stewardship guideline on urinary tract infection prescription patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Increasing resistance in community-acquired urinary tract infections in Latin America, five years after the implementation of national therapeutic guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

Metabolism, Excretion, and Pharmacokinetics of [14C]Tigecycline, a First-In-Class Glycylcycline Antibiotic, after Intravenous Infusion to Healthy Male Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.778827

10.1517/14656566.2013.778827

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference